DOMPE U.S. INC.

DOMPE U.S. INC. specializes in the manufacturing and supply of specialized pharmaceutical preparations, with deep expertise in the production and distribution of ophthalmic solutions for critical patient care. Their core capability centers on the end-to-end delivery of active pharmaceutical ingredients and finished dosage forms, particularly for niche therapeutic indications such as neurotrophic keratitis, as evidenced by consistent provision of OXERVATE (cenegermin-bkbj) 0.002% ophthalmic solution. The contractor demonstrates technical proficiency in aseptic manufacturing, cold chain logistics, and emergency pharmaceutical response protocols, ensuring timely access to life-impacting therapies under urgent clinical demand. Their ability to rapidly scale production and distribution of a biologic eye drop under time-sensitive conditions reflects advanced GMP compliance, regulatory agility, and supply chain resilience tailored to federal healthcare needs. The Department of Veterans Affairs is their sole and consistent federal partner, with recurring contracts focused on procuring OXERVATE for veteran patients with rare ocular conditions. This sustained relationship indicates a trusted, mission-critical role in VA’s specialty pharmacy network, where the contractor serves as a reliable source for high-complexity, low-volume therapeutics requiring strict temperature control and regulatory oversight. DOMPE U.S. INC. operates exclusively within NAICS 325412, focusing on pharmaceutical preparation manufacturing with a vertical specialization in ophthalmic biologics. Their market positioning is that of a niche supplier for FDA-approved, specialty ophthalmic drugs with limited commercial alternatives, serving government health systems requiring assured access to orphan therapeutics. As a 2L entity headquartered in San Mateo, California, DOMPE U.S. INC. functions as a U.S.-based pharmaceutical manufacturer without federal certifications such as 8(a), HUBZone, or WOSB. Their geographic presence is centralized, with operations aligned to support federal pharmaceutical procurement mandates through direct manufacturing and distribution capabilities.